Tcr2 Therapeutics's receivables is $0.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2023), TCRR shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, TCRR's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Tcr2 Therapeutics is outperforming or lagging.
Tracking TCRR's receivables over time shows whether Tcr2 Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this receivables page, Stockcircle has Tcr2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.
Tcr2 Therapeutics's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.